Could a white blood cell booster help shrink breast tumors before surgery?
NCT ID NCT03571633
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether adding pegfilgrastim (a drug that increases white blood cells) to standard chemotherapy and trastuzumab can help the immune system better attack HER2-positive breast cancer before surgery. About 90 women with early-stage, operable breast cancer will take part. The main goal is to see if more tumors completely disappear after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHRU Besançon
Besançon, 25000, France
-
Centre Hospitalier Annecy Genevois
Pringy, France
-
Centre Hospitalier Universitaire de Saint Etienne
Saint-Etienne, France
-
Centre Leon Berard
Lyon, France
-
Centre de Lutte contre le Cancer Jean Perrin
Clermont-Ferrand, 63000, France
-
Clinique Charcot
Sainte-Foy-lès-Lyon, France
-
Groupe Hospitalier Mutualiste de Grenoble
Grenoble, 38000, France
-
Hopital Prive Jean Mermoz
Lyon, France
-
Institut Sainte Catherine
Avignon, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer
- Can a new drug outsmart resistant breast cancer?
- Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?